Alpha Tau Medical Warrant(DRTSW)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

DRTSW Alpha Tau Medical Warrant

交易中 08-24 09:52:03 EDT

4.09

-0.15

-3.54%

最高4.25	最低4.09	成交量6,727
今开4.22	昨收4.24	日振幅3.77%
总市值2.88亿	流通市值2.88亿	总股本7,038万
成交额2.83万	换手率0.01%	流通股本7,038万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"DRTSW","market":"US","secType":"STK","nameCN":"Alpha Tau Medical Warrant","latestPrice":4.09,"timestamp":1787579441780,"preClose":4.24,"halted":0,"volume":6727,"delay":0,"changeRate":-0.03537735849056612,"floatShares":70380571,"shares":70380571,"eps":-0.5213,"marketStatus":"交易中","change":-0.15,"latestTime":"08-24 09:52:03 EDT","open":4.2156,"high":4.25,"low":4.09,"amount":28258.485612,"amplitude":0.037736,"askPrice":4.25,"askSize":1081,"bidPrice":4.07,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-0.5213,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":4.24,"volumeRatio":1.831723},"requestUrl":"/m/hq/s/DRTSW","defaultTab":"news","newsList":[{"id":"1111080195","title":"Alpha Tau Medical联合疗法展现积极数据：中位总生存期18.2个月，中位无进展生存期5.4个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1111080195","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111080195?lang=zh_cn&edition=full","pubTime":"2026-07-21 20:32","pubTimestamp":1784637134,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical公司公布了其Alpha DaRT技术联合帕博利珠单抗（Pembrolizumab）治疗晚期实体瘤患者的临床数据。结果显示，患者的中位总生存期（OS）达到18.2个月，中位无进展生存期（PFS）为5.4个月。这一数据为该联合疗法的进一步开发提供了积极的信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRTSW","BK4082","DRTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151894607","title":"Alpha Tau Medical获FDA批准完成复发性胶质母细胞瘤试验招募并新增两处美国临床中心；早期中期结果展现100%局部疾病控制","url":"https://stock-news.laohu8.com/highlight/detail?id=1151894607","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151894607?lang=zh_cn&edition=full","pubTime":"2026-06-11 20:33","pubTimestamp":1781181205,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical已获得美国食品药品监督管理局的批准，将完成其针对复发性胶质母细胞瘤的“Regain”临床试验的患者招募工作，并将在美国增设两处临床研究中心。该公司公布的中期初步数据显示，试验取得了100%的局部疾病控制率。胶质母细胞瘤复发后的治疗选择通常有限，且预后严峻，因此任何积极的临床数据都备受关注。公司计划在完成招募后，继续收集数据以评估治疗的长期安全性和有效性。此次FDA的批准标志着该试验向前迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","DRTS","DRTSW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110059035","title":"Alpha Tau Medical与Tolmar获前列腺癌美国独家授权及膀胱癌选择权","url":"https://stock-news.laohu8.com/highlight/detail?id=1110059035","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110059035?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:31","pubTimestamp":1780489891,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical与Tolmar公司已获得前列腺癌在美国的独家商业化权利，同时Tolmar还获得了针对膀胱癌的潜在商业化选择权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRTSW","DRTS","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170591238","title":"Alpha Tau Medical与Tolmar达成协议：后者将投入1500万美元用于制造，并以每股11.99美元价格认购2000万美元股权，里程碑付款最高可达1.615亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1170591238","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170591238?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:31","pubTimestamp":1780489886,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical宣布与Tolmar达成一项战略投资与合作协议。根据协议条款，Tolmar将进行两笔关键投资：首先，直接投入1500万美元用于支持Alpha Tau Medical的制造能力建设；其次，以每股11.99美元的价格认购价值2000万美元的Alpha Tau Medical股权。\n此外，协议还包含基于未来里程碑成就的潜在付款。如果Alpha Tau Medical成功达成特定的开发与商业里程碑，Tolmar可能支付总额最高达1.615亿美元的额外款项。这一合作框架旨在加速Alpha Tau Medical专有技术的开发和商业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRTSW","BK4082","DRTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150556910","title":"Alpha Tau Medical公布2026年ASCO年会Alpha Dart®胰腺癌研究强劲总生存期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1150556910","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150556910?lang=zh_cn&edition=full","pubTime":"2026-06-01 21:04","pubTimestamp":1780319084,"startTime":"0","endTime":"0","summary":"在2026年美国临床肿瘤学会（ASCO）年会上，Alpha Tau Medical公司公布了其Alpha Dart®技术用于胰腺癌治疗的研究数据，结果显示患者总生存期（OS）获得显著改善。这一积极成果进一步验证了该创新疗法的潜力。\n相关数据在本次国际肿瘤学盛会上进行了展示，引发了业界关注。胰腺癌因其治疗难度大、预后差而被称为“癌王”，任何在生存期方面的突破都意义重大。Alpha Dart®技术展现出的疗效，为患者提供了新的希望。\n公司表示，这些数据将支持其后续的临床开发与监管申请工作。随着研究的深入，该疗法有望在未来为更多胰腺癌患者提供有效的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRTSW","BK4082","DRTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136489417","title":"Alpha Tau Medical获FDA批准IDE补充申请 将Alpha Dart® Impact试验范围扩展至接受吉西他滨联合Abraxane®治疗胰腺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1136489417","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136489417?lang=zh_cn&edition=full","pubTime":"2026-04-23 21:04","pubTimestamp":1776949489,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical宣布，美国食品药品监督管理局(FDA)已批准其研究器械豁免(IDE)补充申请，允许将Alpha Dart® Impact临床试验的适用范围扩展至正在接受吉西他滨联合Abraxane®（白蛋白结合型紫杉醇）治疗的胰腺癌患者群体。\n这一监管里程碑意味着更多晚期胰腺癌患者现可参与该创新放射治疗技术的临床评估。Alpha Dart®平台采用专有α射线发射器，能够实现肿瘤组织的精准靶向治疗。\n试验范围的拓展将有助于收集更全面的临床数据，为未来治疗方案的优化提供科学依据。胰腺癌作为恶性程度极高的肿瘤类型，此次试验扩展有望为患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRTS","DRTSW","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196198472","title":"Alpha Tau Medical在欧洲Acapella临床试验中成功应用Alpha Dart®治疗首例胰腺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1196198472","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196198472?lang=zh_cn&edition=full","pubTime":"2026-04-23 21:02","pubTimestamp":1776949323,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical宣布，其在法国开展的多中心Acapella临床试验取得重要进展，成功使用Alpha Dart®放射疗法为欧洲首例胰腺癌患者完成治疗。这一里程碑事件标志着该创新癌症治疗技术在消化系统肿瘤领域的应用实现新突破。\n胰腺癌作为临床治疗难度极高的恶性肿瘤类型，此次治疗成果为后续扩大适应症范围提供了重要临床依据。多中心试验设计有助于收集更具代表性的疗效数据，为治疗方案优化奠定基础。\nAlpha Dart®技术通过靶向释放α粒子实现精准肿瘤消融，其独特机制在保持健康组织不受损伤的同时，可有效提升局部肿瘤控制率。该技术此前已在其他癌种治疗中展现出良好应用前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRTS","BK4082","DRTSW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110639951","title":"Alpha Tau Medical 宣布 Alpha Dart® 胰腺癌数据将首次在2026年消化疾病周进行口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1110639951","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110639951?lang=zh_cn&edition=full","pubTime":"2026-03-31 21:17","pubTimestamp":1774963022,"startTime":"0","endTime":"0","summary":"Alpha Tau Medical 近日宣布，其针对胰腺癌的 Alpha Dart® 技术相关数据，将于2026年消化疾病周上首次以口头报告形式公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","DRTSW","DRTS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alphatau.com","stockEarnings":[{"period":"1week","weight":0.1337},{"period":"1month","weight":0.2848},{"period":"3month","weight":0.7131},{"period":"6month","weight":2.7857},{"period":"1year","weight":14.4858},{"period":"ytd","weight":11.4706}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Alpha Tau Medical Ltd.是一家于2016年在以色列成立的公司。该公司是一家临床阶段的肿瘤治疗公司，专注于利用先天的相对生物有效性和短程α颗粒作为实体瘤的局部放射治疗。该公司专有的Alpha DaRT技术旨在利用alpha粒子的特定治疗特性，同时旨在克服甚至利用alpha辐射范围有限的传统缺点，以获得潜在利益。该公司已经在世界各地的临床地点进行了多项临床试验，评估并继续评估Alpha DaRT技术治疗浅表病变，即皮肤、头部或颈部肿瘤的可行性、安全性和有效性。","yearOnYearQuotes":[{"month":1,"riseRate":1,"avgChangeRate":0.894988},{"month":2,"riseRate":0.5,"avgChangeRate":0.003578},{"month":3,"riseRate":0.25,"avgChangeRate":-0.139972},{"month":4,"riseRate":0.2,"avgChangeRate":-0.160543},{"month":5,"riseRate":1,"avgChangeRate":0.450897},{"month":6,"riseRate":0.6,"avgChangeRate":0.06451},{"month":7,"riseRate":0.2,"avgChangeRate":-0.07313},{"month":8,"riseRate":0.6,"avgChangeRate":0.170532},{"month":9,"riseRate":0.5,"avgChangeRate":0.006417},{"month":10,"riseRate":0,"avgChangeRate":-0.138065},{"month":11,"riseRate":0.75,"avgChangeRate":0.165827},{"month":12,"riseRate":0,"avgChangeRate":-0.159553}],"exchange":"NASDAQ","name":"Alpha Tau Medical Warrant","nameEN":"Alpha Tau Medical Warrant"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alpha Tau Medical Warrant(DRTSW)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Alpha Tau Medical Warrant(DRTSW)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Alpha Tau Medical Warrant,DRTSW,Alpha Tau Medical Warrant股票,Alpha Tau Medical Warrant股票老虎,Alpha Tau Medical Warrant股票老虎国际,Alpha Tau Medical Warrant行情,Alpha Tau Medical Warrant股票行情,Alpha Tau Medical Warrant股价,Alpha Tau Medical Warrant股市,Alpha Tau Medical Warrant股票价格,Alpha Tau Medical Warrant股票交易,Alpha Tau Medical Warrant股票购买,Alpha Tau Medical Warrant股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alpha Tau Medical Warrant(DRTSW)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Alpha Tau Medical Warrant(DRTSW)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}